Abstract
The KEYNOTE-355 trial showed that programmed death receptor 1 (PD-1) inhibitor pembrolizumab, in the combined positive score (CPS) ≥10 population and combined with chemotherapy (nab-paclitaxel, paclitaxel or gemcitabine), improves survival over placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic TNBC. Based on those findings, pembrolizumab was approved in Colombia for that population. Likewise, atezolizumab plus nab-paclitaxel (A+NP), is another treatment option available for 1L metastatic TNBC. This study evaluated cost-effectiveness of pembrolizumab + nab-paclitaxel versus A+NP in CPS ≥10 population from a third payer perspective in Colombia.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
